公开(公告)号：US20130181553A1

公开(公告)日：2013-07-18

申请号：US13788848

申请日：2013-03-07

Applicant: Dezheng Wu ,  Lars Gertmar ,  Waqas Arshad ,  Cedric Monnay ,  Magnus Byggnevi ,  Frederic Tholence

Inventor： Dezheng Wu ,  Lars Gertmar ,  Waqas Arshad ,  Cedric Monnay ,  Magnus Byggnevi ,  Frederic Tholence

IPC: H02K7/18 ,  H02K9/00

CPC classification number: H02K7/183 ,  H02K3/28 ,  H02K7/1838 ,  H02K9/005 ,  H02K11/046 ,  H02K19/26 ,  H02K55/02 ,  H02K2213/06 ,  H02K2213/12 ,  H02P29/0241 ,  H02P29/032 ,  Y02E10/725 ,  Y02E40/622

Abstract: An electrical machine with a rotor or the stator including a plurality of discrete field modules, and the other one of the rotor and the stator including a plurality of armature coils connected to different power converters. Each field module includes one or more field coils which can be activated independent of the field coils of the neighbouring field modules. When at least one of the field coils is inactivated, e.g. because of a defect, each of the power converters is allowing less power to pass through when an armature coil connected to it is moving over an inactivated field coil, and more power to pass through when the armature coil connected to it is moving over an activated field coil.

Abstract translation: 一种具有转子或定子的电机，包括多个离散现场模块，并且转子和定子中的另一个包括连接到不同功率转换器的多个电枢线圈。 每个场模块包括一个或多个可以独立于相邻现场模块的励磁线圈激活的励磁线圈。 当至少一个励磁线圈失活时，例如， 由于缺陷，当与其连接的电枢线圈移动超过失活的励磁线圈时，每个电力转换器允许较少的功率通过，并且当连接到其的电枢线圈移动到激活的电源线上时，更多的电力通过 励磁线圈

公开(公告)号：US20060263331A1

公开(公告)日：2006-11-23

申请号：US10741161

申请日：2003-12-19

Applicant: Gang Chen ,  Xinjiang Du ,  Dezheng Wu ,  Weijing Zhang ,  Shirley Chen

Inventor： Gang Chen ,  Xinjiang Du ,  Dezheng Wu ,  Weijing Zhang ,  Shirley Chen

IPC: A61K38/19 ,  A61K38/17 ,  A61K31/704 ,  A61K31/522 ,  A61K33/24

CPC classification number: A61K45/06 ,  A61K38/1816 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/208 ,  A61K38/21 ,  A61K2300/00

Abstract: Improved methods for treating neoplastic diseases such as cancer are provided by using muteins of human tumor necrosis factor-alpha (TNF-α). Compared to wild-type human TNF-α these therapeutic TNF muteins have higher specific anti-tumor activity, but with much reduced systemic toxicity and milder side effects such chills and fever. In addition, potentially synergistic, novel combinations of the inventive TNF-α muteins with other anti-neoplastic agents are provided for effectively treating patients having particular types of cancer or malignancy or at particular stages of cancer development, and for mitigating resistance of the patients to treatment of non-TNF antineoplastic agents.

Abstract translation: 通过使用人肿瘤坏死因子-α（TNF-α）的突变蛋白来提供治疗肿瘤疾病如癌症的改进方法。 与野生型人TNF-α相比，这些治疗性TNF突变蛋白具有更高的特异性抗肿瘤活性，但是具有大大降低的全身毒性和较轻的副作用，如发冷和发烧。 另外，提供本发明的TNF-α突变蛋白与其它抗肿瘤剂的潜在协同，新颖的组合，用于有效治疗具有特定类型的癌症或恶性肿瘤或癌症发展的特定阶段的患者，并且为了减轻患者的耐药性 治疗非TNF抗肿瘤药物。